Clark 1975.
Methods | Allocation: pre‐randomised list, blocks of 3, provided by drug company. Blindness: double (identical capsules). Design: 3 parallel groups, single centre. Duration: 4 weeks. Analysis: intention‐to‐treat performed only for some outcomes. Country: USA. | |
Participants | Diagnosis: schizophrenia, confirmed by research psychiatry. N=42. Age: range: 21‐57 years. Sex: M 21, F 16. Setting: hospital. History: newly admitted chronic patients. Excluded: < 2 years of illness; < 18 years of age; mental deficiency, epilepsy, organic brain disease, metabolic disorders, liver, renal or cardiac disease. | |
Interventions | 1. Trifluoperazine: dose 10 mg/day initially, then increasing to maximum 50 mg/day (mean 36 mg). N=14. 2. Loxapine: dose 20 mg/day initially, then increased to maximum 100 mg/day, (mean 71mg). N=15. 3. Placebo: 2‐10 capsules. N=13. | |
Outcomes | Leaving the study early.
Side effects: (total; EPS; insomnia; weight; EKG).
Global state: (CGI; use of additional sedation).
Laboratory tests. Unable to use ‐ Mental state: (BPRS ‐ no SD). Efficacy: (analysis of covariance ‐ no usable data). Behaviour: (NOSIE ‐ no usable data). Physiological measures: (BP, pulse ‐ no data). |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |